Jaguar Health, Inc. (JAGX) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Mytesi® (crofelemer), a product of our wholly owned subsidiary, Napo Pharmaceuticals, is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Crofelemer is in development for multiple possible follow-on indications, including the prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, as well as orphan drug indications for infants and children with congenital diarrheal disorders (CDDs); short bowel syndrome (SBS); supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and for idiopathic/functional diarrhea. In addition, a second-generation proprietary anti secretory agent, lechlemer, is in development for the symptomatic relief of cholera-related diarrhea. In September 2020, Jaguar launched the Entheogen Therapeutics Initiative to support the discovery and development of novel, plant-based medicines derived from psychoactive plants for treatment of mental health conditions.